Could fibulin-1 and fibulin-5 serve as rule-out tests for non-ST-elevation myocardial infarction in the emergency setting?
Fibulin-1 and fibulin-5 belong to the fibulin family of extracellular glycoproteins. Both are expressed in the vessel wall and believed to have protective properties against vascular damage. We aimed to investigate whether fibulin -1 and-5 have any role in ruling out non-ST-elevation myocardial infarction (NSTEMI) in the emergency setting. Forty-eight patients were enrolled in the NSTEMI group and 42 subjects (who presented with chest pain and were diagnosed as non-coronary chest pain after comprehensive evaluation including coronary angiography were recruited in the control group (non-coronary group). Blood samples for fibulin-1, fibulin-5 and troponin I measurements were drawn on admission to the emergency department. Demographic features of the patients with NSTEMI and control were similar. Median Fibulin-1 (96.9 [20-503] μg/ml vs. 111.5 [71-457] μg/ml, P = 0.01) and median Fibulin-5 levels (38 [15-509] ng/ml vs. 57 [26-631] ng/ml, P <0.001) were significantly lower in patients with NSTEMI when compared to those with NCAs. ROC curve analysis provided 105.6 μg/ml for admission fibulin-1 level and 49.4 ng/ml for admission Fibulin-5 level as cut-off values to rule-out NSTEMI. The present study demonstrates for the first time that fibulin-1 and fibulin-5 might be used for ruling out acute NSTEMI in patients admitted to the emergency department with acute chest pain. This preliminary study constitutes a core for future research studying the diagnostic role of fibulin -1 and -5 in patients with acute coronary syndromes.